Adam Giermasz, M.D., Ph.D. for UC Davis Health

Adam Giermasz, M.D., Ph.D.

Associate Professor of Medicine

To see if Adam Giermasz is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).



Adult Hemophilia

Benign and Malignant Hematology


Internal Medicine



Internal Medicine

Locations and Contact

Midtown Multi Specialty

3160 Folsom Blvd
Sacramento, CA 95816

Get Directions

Additional Numbers

Clinic Phone


Clinic Fax


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Giermasz believes in high quality, innovative, and compassionate care of his patients. Dr. Giermasz believes in a team-based approach to patient care, utilizing expertise of nurses, pharmacists, social workers, and consultants to provide complete care for his patients.

Clinical Interests

Adam Giermasz co-directs the Hemophilia Treatment Center. He specializes in hemophilia, coagulation and thrombosis disorders.

Research/Academic Interests

Dr. Giermasz' research includes studies in new therapeutics with use of next generation clotting factor, bypassing agents and gene therapy; in addition he is interested in clinical projects aiming for quality of life improvement in patients with bleeding disorders.


Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.S., Biology, Chemistry, III Secondary School - Lyceum, Warsaw, Poland 1992

Medical School

M.D., Medical University of Warsaw, Warsaw, Poland 1998

Other School

Ph.D., Medical University of Warsaw, Warsaw, Poland 2002


Medicine, Military School of Medicine, Warsaw, Poland 1998-1999


Medicine, University of Pittsburgh Medical Center, Pittsburgh PA 2005-2006


Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh PA 2006-2008


Hematology/Oncology, UC San Francisco Medical Center, San Francisco CA 2008-2011

Top 10 Clinical Research Achievement Award for coauthored NEJM publication: "Hemophilia B Gene Therapy”, 2019

Annual Teaching Award, Medical University of Warsaw, 2000

National award and grant for young scholars of The Foundation for Polish Science (FNP), 2000

Scientific Award, Medical University of Warsaw, 1998

To view a detailed list of Dr. Giermasz's publications, please click here.

Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B; GENEr8-1 Trial Group. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi:10.1056/NEJMoa2113708. PMID:35294811.

Escobar M, Luck J, Averianov Y, Ducore J, Fernández MFL, Giermasz A, Hart DP, Journeycake J, Kessler C, Leissinger C, Mahlangu J, Martinez LV, Miesbach W, Mitha IH, Quon D, Reding MT, Schved JF, Stasyshyn O, Vilchevska KV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell IS, Wilkinson TA, Hermans C. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov;27(6):911-920. doi:10.1111/hae.14418. Epub 2021 Oct 6. PMID:34614267.

Rosen S, Tiefenbacher S, Robinson M, Huang M, Srimani J, Mackenzie D, Christianson T, Pasi KJ, Rangarajan S, Symington E, Giermasz A, Pierce GF, Kim B, Zoog SJ, Vettermann C. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy. Blood. 2020 Nov 26;136(22):2524-2534. doi:10.1182/blood.2020005683. PMID:32915950.

Von Drygalski A, Giermasz A, Castaman G, Key NS, Lattimore S, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Sawyer EK, Pipe SW. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019 Nov 12;3(21):3241-3247. doi:10.1182/bloodadvances.2019000811. Erratum in: Blood Adv. 2020 Aug 11;4(15):3668. PMID:31698454.

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi:10.1056/NEJMoa1708538. PMID:29211678.

Tobase P, Mahajan A, Francis D, Leavitt AD, Giermasz A. A gap in comprehensive care: Sexual health in men with haemophilia. Haemophilia. 2017 Jul;23(4):e389-e391. doi:10.1111/hae.13276. Epub 2017 Jun 2. PMID:28574623.

Escobar MA, Tehranchi R, Karim FA, Caliskan U, Chowdary P, Colberg T, Giangrande P, Giermasz, A, Mancuso ME, Serban M, Tsay W, Mahlangu JN. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan;23(1):67-76. doi:10.1111/hae.13041. Epub 2016 Aug 1. PMID:27480487.

Kono M, Nakamura Y, Suda T, Uchijima M, Tsujimura K, Nagata T, Giermasz, AS, Kalinski P, Nakamura H, Chida K. Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vaccine. 2012 Mar 30;30(16):2633-9. doi:10.1016/j.vaccine.2012.02.026. Epub 2012 Feb 22. PMID:22365841.

Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 2009 Aug;58(8):1329-36. doi:10.1007/s00262-008-0648-5. Epub 2009 Jan 21. PMID:19156413.